Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

Table 2 Patients’ basic demographic variables and treatments

	Survivors						Non-survivors
Patient ID	2	3	4	8	10	11	1*	5	6	7	9
Hospital	1	1	2	1	2	2	1	2	2	1	2
Cell type**	UC-MSC	UC-MSC	UC-MSC	PL-MSC	PL-MSC	PL-MSC	UC-MSC	UC-MSC	UC-MSC	PL-MSC	PL-MSC
Age (years)***	60–65	55–60	65–70	60–65	40–45	45–50	65–70	50–55	55–60	35–40	60–65
Sex (1/2)***	2	2	1	1	1	1	2	1	1	1	1
Weight (kg)	80	69	60	95	85	103	80	80	87	85	94
Underlying disease	HTN, DM	–	CLL	CMP, DM	–	HTN	HTN, DM	–	–	–	DM
Treatment protocol	HCQ, Kaletra	HCQ, Kaletra	HCQ, Kaletra, Azithromycin, IVIG, Ribavarin	HCQ, Kaletra	Meropenem, Vancomycin, IVIG, Favipiravir	Kaletra, Meropenem, Vancomycin, Tamiflu, IVIG, Favipiravir	HCQ, Kaletra	HCQ, Kaletra, Azithromycin, IVIG, + ECMO	Kaletra, Ribavirin, Vancomycin, Imiper, IVIG	HCQ, Kaletra	Kaletra, Meropenem, Colistin, IVIG
qRT-PCR	+	+	+	+	+	+	−	+	+	+	+

HCQ hydroxychloroquine, HTN hypertension, DM diabetes mellitus, IVIG intravenous immunoglobulin, ECMO extracorporeal membrane oxygenation, qRT-PCR quantitative reverse transcription-polymerase chain reaction, CMP cardiomyopathy, CLL chronic lymphocytic leukemia, UC-MSC umbilical cord mesenchymal stem cells, PL-MSC placental MSC
*qRT-PCR in this patient was initially negative but history, clinical presentation, and radiography of the patient were indicative of COVID-19 infection
**UC-MSCs were freeze/thawed prior to infusion; however, PL-MSCs were freshly administered
***To avoid the patients/participants identity being revealed, age presented as a range and gender as (1/2)

ISSN: 1757-6512